Details for Patent: 8,420,596
✉ Email this page to a colleague
Which drugs does patent 8,420,596 protect, and when does it expire?
Patent 8,420,596 protects VIEKIRA XR, VIEKIRA PAK (COPACKAGED), and TECHNIVIE, and is included in three NDAs.
Protection for TECHNIVIE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and thirteen patent family members in forty-one countries.
Summary for Patent: 8,420,596
Title: | Macrocyclic hepatitis C serine protease inhibitors |
Abstract: | The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. |
Inventor(s): | Ku; Yiyin (Buffalo Grove, IL), McDaniel; Keith F. (Wauconda, IL), Chen; Hui-Ju (Grayslake, IL), Shanley; Jason P. (Chicago, IL), Kempf; Dale J. (Libertyville, IL), Grampovnik; David J. (Waukegan, IL) |
Assignee: | Abbott Laboratories (Abbott Park, IL) Enanta Pharmaceuticals, Inc. (Watertown, MA) |
Application Number: | 12/584,716 |
Patent Claim Types: see list of patent claims | Compound; Composition; |
Drugs Protected by US Patent 8,420,596
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | VIEKIRA XR | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | TABLET, EXTENDED RELEASE;ORAL | 208624-001 | Jul 22, 2016 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
Abbvie | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
Abbvie | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,420,596
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 073568 | ⤷ Try a Trial | |||
Argentina | 086181 | ⤷ Try a Trial | |||
Argentina | 093924 | ⤷ Try a Trial | |||
Australia | 2009292182 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |